Change from baseline in weekly average of daily NRS pain score to Week 12 is reported. The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This was recorded on a daily basis at approximately the same time every morning via electronic patient recorded outcome (ePRO) diary. A two-step multiple imputation procedure was used to address missing post-baseline scores.

Full analysis set (FAS) included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.

The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to osteoarthritis (OA) in the target knee. Each question was scored on a NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Change from baseline in WOMAC pain subscale to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.

The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC physical function (PF) subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Change from baseline in WOMAC physical function to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.

The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Change from baseline in PGA of OA to Week 12 is reported. A two-step multiple imputation procedure was used to address missing post-baseline scores.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received.

The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to OA in the target knee. Each question was scored on an NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Change from baseline in WOMAC pain subscale to Weeks 2, 4,6, 8, 10, and 18 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC PF subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Change from baseline in WOMAC physical function to Weeks 2, 4, 6, 8, 10, and 18 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The WOMAC overall score consisted of all 24 questions reported in the WOMAC questionnaire to assess: i) pain subscale, ii) PF subscale and iii) stiffness subscale. WOMAC overall score was calculated as the mean score from all 24 questions each scored on a Likert scale from 0 to 10 where higher scores represent worse outcome. Change from baseline in weekly average of WOMAC overall score to Weeks 2, 4, 6, 8, 10, 12, and 18 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The WOMAC stiffness function subscale consists of 2 questions assessing stiffness due to OA in the target knee. Stiffness is defined as a sensation of decreased ease of movement in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC stiffness function subscale score is calculated as the mean score from the 2 questions, where higher scores represent higher stiffness. Change from baseline in WOMAC stiffness score to Weeks 2, 4, 6, 8, 10, 12, and 18 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Change from baseline in PGA of OA to Weeks 2, 4, 8, 10, and 18 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The OMERACT-OARSI responder index is calculated from the WOMAC Pain subscale, the WOMAC Physical Function Subscale and the PGA of OA. A participant is classified as a responder if: 1. >= 2-point absolute change from Baseline to Week X or a >= 50% improvement is reported in the WOMAC Pain or the PF subscales; 2. At least 2 of the following 3 conditions are true: >= 1-point absolute change from Baseline to Week X or >= 20% improvement is reported in the WOMAC Pain subscale, >= 1-point absolute change from Baseline to Week X or >= 20% improvement is reported in the WOMAC PF subscale or >= 1-point absolute change from Baseline to Week X is reported in the PGA of OA. Percentage of responder participants are reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The PGA of OA was a 5-point Likert scale used to assess symptoms and activity impairment due to OA of the knee. Participants were asked to identify a number from 1 = "very good (asymptomatic and no limitation to normal activities)" to 5 = "very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)" based on the question "Considering all the ways that OA of the knee affects you, how are you feeling today?". Percentage of participants with improvement of >= 2 points in PGA of OA at Weeks 2, 4, 8, 12, and 18 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This will be recorded on a daily basis at approximately the same time every morning via ePRO diary. Change from baseline in weekly average of daily NRS to Weeks 2, 4, 6, 8, 10, and 18 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The NRS is an 11-point Likert scale used to assess pain, where participants were asked to describe their average pain in the target knee by identifying a number from 0 = "no pain" to 10 = "most severe pain imaginable over the previous 24 hours". This will be recorded on a daily basis at approximately the same time every morning via ePRO diary. Percentage of participants with >= 30% and >= 50% reductions in weekly average of daily NRS pain score are reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The WOMAC multiscale index is used to assess pain, stiffness, and joint functionality in the past 48 hours in participants with OA of the knee or hip. The WOMAC pain subscale consists of 5 questions assessing the participant's pain due to OA in the target knee. Each question was scored on an NRS scale from 0 to 10, and the WOMAC pain subscale score is calculated as the mean score from all 5 questions, where higher scores represent higher pain. Percentage of participants with >= 30% and >= 50% reductions in WOMAC pain subscale score over time are reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

The WOMAC PF subscale consists of 17 questions assessing the participant's difficulty in performing activities of daily living due to OA in the target knee. Each question is scored on an NRS scale from 0 to 10, and the WOMAC PF subscale score is calculated as the mean score from all 17 questions, where higher scores represent worse function. Percentage of participants with >= 30% and >= 50% reductions in WOMAC physical function subscale over time are reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

Serum concentration of MEDI7352 is reported.

Pharmacokinetic (PK) analysis set included participants who received at least one dose of double-blind study treatment per the protocol for whom any post-baseline PK data are available and who did not violate or deviate from the protocol in ways that would significantly affect the PK analyses. Number of participants analyzed (N) denotes those participants who were analyzed for this outcome measure. Number analyzed (n) denotes those participants who had adequate serum samples.

Number of participants with ADA to MEDI7352 are reported. Treatment-induced ADA positive is defined as ADA negative at baseline and positive at least 1 post-baseline ADA assessment. Treatment-boosted ADA positive is defined as ADA positive at baseline, and the baseline titre is boosted by greater than the variability of the assay (commonly 4-fold) at >= 1 post-baseline timepoint. Persistent positive is defined as ADA negative at baseline and having at least 2 post-baseline ADA positive assessments (with >= 16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as ADA negative at baseline and at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

ADA evaluable participants included all participants in the safety analysis set who have a non-missing baseline and at least one non-missing post-baseline ADA results. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who had adequate ADA sample.

The ADA titre in participants who were ADA positive at baseline and/or post-baseline is reported.

ADA evaluable participants included all participants in safety analysis set who have non-missing baseline and at least 1 non-missing post-baseline ADA results. Number of participants analyzed (N): number of participants who were ADA positive at baseline and/or post-baseline. Number analyzed (n): participants who had adequate ADA sample.

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.

Number of participants with clinically significant findings in physical examination reported as TEAE are reported. A physical examination included assessments of general appearance, skin, head and neck, examination of the oral cavity for any lesions, lymph nodes, thyroid, abdomen (bowel sounds, liver, and spleen palpation), back (including costovertebral angle tenderness), musculoskeletal/extremities, cardiovascular, and respiratory systems.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.

Number of participants with clinically significant abnormal findings in neurological examination is reported. The neurological examination included assessment of mental status, cranial nerves, motor examination (muscle strength and tone), upper and lower extremity deep tendon reflexes, plantar responses, sensory system examination, coordination, and gait.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.

The TNSn, is a semiquantitative clinical assessment of peripheral nervous system function. The TNSn assessment is collected as scores of motor symptom, autonomic symptom, pin sensibility, sensory symptom, and vibration sensibility score. Each neuropathy item is scored on a 0 to 4 scale with total score ranging from 0 to 20. Higher total scores correlate with more severe neuropathy.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

Change from baseline in weight (kg) to Week 12 is reported.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants evaluated at Week 12

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormalfinding in the vital sign parameters (body temperature, supine and standing blood pressure, pulse rate, and respiratory rate).

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.

The SAS is an instrument that measures autonomic symptoms used for assessing autonomic neuropathies in clinical trials. The SAS scale evaluates the presence of symptoms and the degree of severity. The SAS consists of 11 questions in women and 12 questions in men. Each question has a Yes or No answer to symptoms occurring 6 months prior to investigational product (IP) administration. Questions answered with "Yes" are further rated by asking the participant how much each symptom is bothering him or her. Each answer is scored on a scale from 1 to 5 where 1 = not at all and 5 = a lot, and a total symptom impact score is determined. The SAS total impact score is the total of the scores from each question (11 for women and 12 for men). The minimum score is 0 and the maximum is 55 for women and 60 for men. A higher score indicates worse autonomic dysfunction.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who had adequate SAS impact score.

Number of participants with clinically significant abnormal ECGs are reported.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received. Number of participants analyzed (N) denotes the number of participants who were evaluable for the specified outcome measure. Number analyzed (n) denotes those participants who were evaluable at the specified time point.

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.

Change from baseline in C-reactive protein level to Week 12 is reported.

FAS included all randomized participants analyzed according to the intent-to-treat principle whereby randomized study treatment will be analyzed regardless of the study treatment actually received. Number of participants analyzed (N) denotes the number of participants evaluated at Week 12.

Number of participants with injection site reactions are reported.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.

Number of participants with abnormal X-ray and/or MRI of large joints is reported.

Safety analysis set included all participants who received at least 1 dose of any double-blind study drug and were analyzed according to the treatment they actually received.